Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05001152 · ClinicalTrials.gov registry record · Phase 1

Taste Assessment of Ozanimod

A Phase 1 study, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
7
Enrollment target

NCT05001152 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 7 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05001152, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
7 participants
Enrollment target

Study Summary

The purpose of this study is to assess the taste characteristics of ozanimod formulations, alone and mixed, in order to develop a pediatric oral form of ozanimod.

Interventions

  • DRUG Ozanimod

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2021-09-09
Est. Completion 2021-09-27
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

What the Registry Record Tells You About NCT05001152

The ClinicalTrials.gov registry entry for NCT05001152 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Ozanimod is the first listed.

NCT05001152 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05001152 about?

NCT05001152 is a clinical study titled "Taste Assessment of Ozanimod". The purpose of this study is to assess the taste characteristics of ozanimod formulations, alone and mixed, in order to develop a pediatric oral form of ozanimod.

What is the current status of trial NCT05001152?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2021-09-09. Estimated completion is 2021-09-27.

What interventions are being tested in trial NCT05001152?

The interventions under investigation include: Ozanimod (DRUG).

Who is sponsoring clinical trial NCT05001152?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.